Skip to main contentSkip to navigation
Sirius Investors

NNNN Stock: Anbio Biotechnology Class A Ordinary Shares Stock Price, Analysis & Insights

Get live NNNN stock price $16.64, comprehensive Anbio Biotechnology Class A Ordinary Shares stock analysis, charts, news, and expert forecast. Real-time NNNN stock data and investment insights.

16.64
2.97%Today
NNNNAnbio Biotechnology Class A Ordinary Shares • NASDAQ Global Select • Healthcare
Market Cap
730.35M
Volume
12.57K
52W High
55.65
52W Low
8.43

Loading chart data...

Anbio Biotechnology Class A Ordinary Shares (NNNN) Overview

Anbio Biotechnology Class A Ordinary Shares (NNNN) is a publicly traded company in the Healthcare sector , specifically within the Medical - Instruments & Supplies industry . As of the latest trading session, NNNN trades at $16.64 with a market capitalization of 730.35M . Over the past 52 weeks, NNNN has traded between $8.43 and $55.65 , with the current price positioned at approximately 17% of...

Key Takeaways

  • Operates in the Healthcare sector (Medical - Instruments & Supplies)
  • Market cap: 730.35M
  • Current price: $16.64
  • 52-week range: $8.43 - $55.65
  • P/E ratio: 110.93

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, Nor...

Company Information

CEO
Michael Lau
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
27

Contact Information

Address
Wilhelm Gutbrod Str 21B
Country
DE

Investment Analysis & Business Insights

Healthcare
Medical - Instruments & Supplies

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 110.9)

Higher growth potential with elevated volatility (Beta: 4.34)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Anbio Biotechnology Class A Ordinary Shares shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Anbio Biotechnology Class A Ordinary Shares
  • Investors should consider how Anbio Biotechnology Class A Ordinary Shares fits within their overall portfolio allocation
  • Premium valuation (P/E: 110.9) requires strong growth to justify

Market Cap

730.35M

P/E Ratio (TTM)

110.93

Beta

4.34

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.